regulatory
confidence high
sentiment positive
materiality 0.90
Outlook Therapeutics receives FDA approval for LYTENAVA (bevacizumab-vikg) for wet AMD
Outlook Therapeutics, Inc.
- LYTENAVA is the first and only FDA-approved ophthalmic bevacizumab for wet AMD in the US.
- Company anticipates 12 years of Reference Product Exclusivity under the BPCIA.
- US anti-VEGF retina market estimated at ~$8.5B annually; commercial launch expected before year-end.
- CEO Bob Jahr: approval establishes a new standard for bevacizumab therapy in wet AMD.
- LYTENAVA already approved in EU and UK; US approval adds a major market.